... Settlement in Principle Would Bring To Close Derivative Lawsuit File... October 2006 ...ST. LOUIS April 8 2008 /- KV PharmaceuticalC...Upon final Court approval of the settlement agreement all privatesec...

Settlement in Principle Would Bring To Close Derivative Lawsuit Filed in

October 2006

ST. LOUIS, April 8, 2008 /PRNewswire-FirstCall/ -- KV Pharmaceutical
Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical
company that develops, manufactures, acquires and markets technology
differentiated branded and generic/non-branded prescription pharmaceutical
products, announced today that it has reached a comprehensive settlement
agreement in principle with the plaintiffs in a derivative lawsuit relating
to the Company's historic stock option granting practices, subject to
limited confirmatory discovery and court approval. Fees and costs awarded
by the Court are expected to be covered by insurance.

Upon final Court approval of the settlement agreement, all private
securities litigation pending against the Company regarding the stock
option matter will be resolved.

"Upon its finalization, the settlement of this litigation will be
another step, along with the recent filing of the Company's Form 10-Q's and
Form 10-K for Fiscal 2007, towards putting the entire option issue behind
us," stated Marc S. Hermelin, Chairman of the Board.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty
pharmaceutical company that develops, manufactures, markets and acquires
technology- distinguished branded and generic/non-branded prescription
pharmaceutical products. The Company markets its technology-distinguished
products through ETHEX Corporation, a national leader in pharmaceuticals
that compete with branded products, and Ther-Rx Corporation, its branded
prescription pharmaceutical subsidiary.

The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or
include assumptions concerning KV's operations, future results and
prospects. Such statements may be identified by the use of words like
"plans", "expects", "aims", "believes", "projects", "anticipates",
"commits", "intends", "estimate", "will", "should", "could" and other
expressions that indicate future events and trends.

All statements that address expectations or projections about the
future, including without limitation, statements about the Company's
strategy for growth, product development, product launches, regulatory
approvals, resolution of litigation and issues pertaining to the Company's
historic stock option granting processes, market position, market share
increases, acquisitions, revenues, expenditures and other financial
results, are forward- looking statements.

All forward-looking statements are based on current expectations and
are subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors, which among others,
could cause actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1)
changes in the current and future business environment, including interest
rates and capital and consumer spending; (2) the difficulty of predicting
FDA approvals, including timing, and that any period of exclusivity may not
be realized; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the possibility that any product launch may be delayed or that
product acceptance may be less than anticipated; (6) reliance on key
strategic alliances; (7) the availability of raw materials and/or products
manufactured for the Company under contract manufacturing arrangements with
third parties; (8) the regulatory environment, including regulatory agency
and judicial actions and changes in applicable law or regulations; (9)
fluctuations in revenues; (10) the difficulty of predicting international
regulatory approval, including timing; (11) the difficulty of predicting
the pattern of inventory movements by the Company's customers; (12) the
impact of competitive response to the Company's sales, marketing and
strategic efforts; (13) risks that the Company may not ultimately prevail
in litigation; (14) completion of the Company's financial statements for
the first, second and third quarters of fiscal 2008; (15) actions by the
Securities and Exchange Commission and the Internal Revenue Service with
respect to the Company's stock option grants and accounting practices; (16)
the risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission; and (17) the impact of credit market
disruptions on the fair value of auction rate securities that we have
acquired as short-term investments.

This discussion is by no means exhaustive, but is designed to highlight
important factors that may impact the Company's outlook. We are under no
obligation to update any of the forward-looking statements after the date
of this release.

(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, ... that it was acquired by Advantage Solutions. The Data Council’s IX-ONE platform ... include the industry’s leading suppliers, brokers, distributors and retailers. The Data Council will ...

(Date:7/26/2017)... Medical Aesthetics, a leading medical aesthetic clinic in Singapore ... several skin conditions from the inside. The natural process ... The skin becomes more transparent due to the thinning of the ... from the sun contributes to aging skin, causing age spots and ... ...